Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

Yagi, Shusuke; Hirata, Yukina; Ise, Takayuki; Kusunose, Kenya; Yamada, Hirotsugu; Fukuda, Daiju; Masdan Salim, Hotimah; Maimaituxun, Gulinu; Nishio, Susumu; Takagawa, Yuriko; Hama, Saori; Matsuura, Tomomi; Yamaguchi, Koji; Tobiume, Takeshi; Soeki, Takeshi; Wakatsuki, Tetsuzo; Aihara, Ken‐ichi; Akaike, Masashi; Shimabukuro, Michio; Sata, Masataka

doi:10.1186/s13098-017-0275-4

Public

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

Published in Diabetology & Metabolic Syndrome • Oct 4, 2017

Authors:

Shusuke Yagi

Yukina Hirata

Takayuki Ise

Abstract

BACKGROUND: It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. METHODS AND RESULTS: We administered 100 mg of cana...

Subject

Canagliflozin

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!